

Effective **November 1, 2024**, the Alberta Biosimilars Initiative will be updated with the following changes that will affect adult members on Alberta government-sponsored drug plans.

**Addition of denosumab biosimilar – all adult patients on Prolia must switch by May 1, 2025**

**1. Update to Alberta Drug Benefit List (ADBL)**

On November 1, 2024, a new denosumab biosimilar drug, Jubbonti, was listed on the Alberta Drug Benefit List (ADBL) for the treatment of osteoporosis and will be subject to the Alberta Biosimilar Initiative.

**2. Coverage**

Effective November 1, 2024, all new denosumab starts for osteoporosis are covered with a biosimilar version of denosumab. Adult patients currently taking Prolia will be required to switch to a biosimilar version by May 1, 2025 to maintain coverage for this molecule through their Alberta government-sponsored drug plan.